These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33037739)

  • 1. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
    Zhang D; Meng F
    ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
    Spinello A; Borišek J; Malcovati L; Magistrato A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
    Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
    Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
    Kim Guisbert KS; Guisbert E
    PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
    Teng T; Tsai JH; Puyang X; Seiler M; Peng S; Prajapati S; Aird D; Buonamici S; Caleb B; Chan B; Corson L; Feala J; Fekkes P; Gerard B; Karr C; Korpal M; Liu X; T Lowe J; Mizui Y; Palacino J; Park E; Smith PG; Subramanian V; Wu ZJ; Zou J; Yu L; Chicas A; Warmuth M; Larsen N; Zhu P
    Nat Commun; 2017 May; 8():15522. PubMed ID: 28541300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
    Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
    Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds.
    Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V
    Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.
    Webb TR; Joyner AS; Potter PM
    Drug Discov Today; 2013 Jan; 18(1-2):43-9. PubMed ID: 22885522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
    Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
    Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.
    Maji D; Grossfield A; Kielkopf CL
    Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194440. PubMed ID: 31707043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
    Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
    Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
    Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
    Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
    Steensma DP; Wermke M; Klimek VM; Greenberg PL; Font P; Komrokji RS; Yang J; Brunner AM; Carraway HE; Ades L; Al-Kali A; Alonso-Dominguez JM; Alfonso-Piérola A; Coombs CC; Deeg HJ; Flinn I; Foran JM; Garcia-Manero G; Maris MB; McMasters M; Micol JB; De Oteyza JP; Thol F; Wang ES; Watts JM; Taylor J; Stone R; Gourineni V; Marino AJ; Yao H; Destenaves B; Yuan X; Yu K; Dar S; Ohanjanian L; Kuida K; Xiao J; Scholz C; Gualberto A; Platzbecker U
    Leukemia; 2021 Dec; 35(12):3542-3550. PubMed ID: 34172893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pre-mRNA splicing and transcription factor Tat-SF1 is a functional partner of the spliceosome SF3b1 subunit via a U2AF homology motif interface.
    Loerch S; Leach JR; Horner SW; Maji D; Jenkins JL; Pulvino MJ; Kielkopf CL
    J Biol Chem; 2019 Feb; 294(8):2892-2902. PubMed ID: 30567737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
    Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
    J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.